Functional polymorphism rs7072793 C>T affect individual susceptibility to breast cancer by modulating CD25 transcription activity

Molecular Carcinogenesis

Volumn 52, Issue 5, 2013, Pages 370-376

  Li, Hongbin ^a   Zhou, Hongfeng ^a   Zhang, Qingyuan ^a   Zhao, Shu ^a   Zhang, Yue ^a   Wang, Yan ^a   Liu, Jinglei ^a   Song, Ying ^a   Yu, Xiaojin ^b   Yu, Yan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

CD25 IL 2R ; Molecular epidemiology; Polymorphisms

Indexed keywords

INTERLEUKIN 2 RECEPTOR ALPHA;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CD4+ CD25+ T LYMPHOCYTE; CHINESE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; T-LYMPHOCYTES, REGULATORY;

EID: 84876123598     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21865     Document Type: Article

References (33)

1. de Rezende LC, Silva IV, Rangel LB, Guimaraes MC. Regulatory T cell as a target for cancer therapy. Arch Immunol Ther Exp (Warsz) 2010; 58: 179-190.
2. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6: 24-37.
3. Hamerman JA, Ogasawara K, Lanier LL. NK cells in innate immunity. Curr Opin Immunol 2005; 17: 29-35.
4. Bohling SD, Allison KH. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: A potential therapeutic target. Mod Pathol 2008; 21: 1527-1532.
5. Zheng J, Yu X, Jiang L, et al. Association between the cytotoxic T-lymphocyte antigen 4 +49G>A polymorphism and cancer risk: A meta-analysis. BMC Cancer 2010; 10: 522.
6. Bach JF. Regulatory T cells under scrutiny. Nat Rev Immunol 2003; 3: 189-198.
7. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949.
8. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001; 193: 1303-1310.
9. Levings MK, Sangregorio R, Roncarolo MG. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001; 193: 1295-1302.
10. Ng WF, Duggan PJ, Ponchel F, et al. Human CD4(+)CD25(+) cells: A naturally occurring population of regulatory T cells. Blood 2001; 98: 2736-2744.
11. Read S, Powrie F. CD4(+) regulatory T cells. Curr Opin Immunol 2001; 13: 644-649.
12. Shevach EM. CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2002; 2: 389-400.
13. von Herrath MG, Harrison LC. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol 2003; 3: 223-232.
14. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199-210.
15. Ohkura N, Sakaguchi S. Regulatory T cells: Roles of T cell receptor for their development and function. Semin Immunopathol 2010; 32: 95-106.
16. Letourneau S, Krieg C, Pantaleo G, Boyman O. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol 2009; 123: 758-762.
17. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008; 26: 453-479.
18. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4: 665-674.
19. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010; 127: 759-767.
20. Jiang L, Zhang C, Li Y, et al. A non-synonymous polymorphism Thr115Met in the EpCAM gene is associated with an increased risk of breast cancer in Chinese population. Breast Cancer Res Treat 2010; 126: 487-495.
21. Lu J, Wei Q, Bondy ML, et al. Promoter polymorphism (-786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer 2006; 107: 2245-2253.
22. Houghton AN, Guevara-Patino JA. Immune recognition of self in immunity against cancer. J Clin Invest 2004; 114: 468-471.
23. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24: 5373-5380.
24. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003; 9: 4404-4408.
25. Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004; 173: 1444-1453.
26. Feuerer M, Hill JA, Mathis D, Benoist C. Foxp3+ regulatory T cells: Differentiation, specification, subphenotypes. Nat Immunol 2009; 10: 689-695.
27. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
28. Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 2006; 16: 115-123.
29. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006; 311: 1924-1927.
30. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 2007; 8: 1353-1362.
31. Caiulo A, Nicolis S, Bianchi P, et al. Mapping the gene encoding the human erythroid transcriptional factor NFE1-GF1 to Xp11.23. Hum Genet 1991; 86: 388-390.
32. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32: 148-152.
33. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 2003; 102: 981-986.